ReviewJournal of gastrointestinal cancer2026

Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Advanced Gastric and Gastroesophageal Junction Cancer: Evidence, Sequencing, Patient Selection, and Clinical Decision-Making.

Tamotsu Sagawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.